Molecular Determinants of the Anticancer Efficacy of Topoisomerase I Inhibitors
文献类型：会议论文
| 作者 | Fung-Ming Siu |
| 出版日期 | 2015 |
| 会议名称 | MMHS-2015 |
| 会议地点 | Shanghai, China |
| 英文摘要 | Camptothecin and its analogs (CPTs) are effective anticancer agents and are the only class of FDA-approved topoisomerase I (top1) inhibitors or cancer treatment. A panel of 60 diverse human cancer cell lines (NCI-60) has been profiled at DNA, RNA, protein and pharmacological levels by the US National Cancer Institute. In this article, we asked the question of what characteristics of the NCI-60 cell lines are associated with the responses (sensitive or resistant) to the CPTs-treatment. In the present study, a total of 3283 mRNAs, 52 microRNAs and 10 proteins were defined as determinant markers, whose expression levels correlate with the cytotoxicity of CPTs across the NCI-60 panel. Bioinformatics analysis was performed to gain insights (associated pathways or gene ontology terms) from the determinant markers. The results suggest that (i) E-cadherin plays an important role in the chemosensitivity to CPTs; (ii) pretreatment of cancer cells with histone deacetylase inhibitors has antagonistic effects on the anticancer efficacy of CPTs; and (iii) the expression levels of the majority of the determinant gene markers do not change upon CPT-treatment. The present study provides detailed analysis on the determinant markers that can be exploited in future studies to ultimately improve the outcome of CPTs-based cancer treatment. We envision our study can be considered as a paradigm of the combined use of the CellMiner database (National Cancer Institute) and the Connectivity Map databases (Broad Institute of MIT and Harvard) to predict drug combination effects. |
| 收录类别 | 其他 |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/6986]  |
| 专题 | 深圳先进技术研究院_数字所 |
| 作者单位 | 2015 |
| 推荐引用方式 GB/T 7714 | Fung-Ming Siu. Molecular Determinants of the Anticancer Efficacy of Topoisomerase I Inhibitors[C]. 见:MMHS-2015. Shanghai, China. |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。